Loading clinical trials...
Loading clinical trials...
The Safety and Efficacy of Rh-Endostatin (Endostar®) Continuous Intravenous Infusion in Combination With Docetaxel/Carboplatin or Pemetrexed/Carboplatin (DC/PC) Regimens for Untreated Stage IIIB/IV Non-small-cell Lung Cancer (NSCLC)
Conditions
Interventions
Endostar
Docetaxel
+2 more
Locations
1
China
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Guangzhou, Guangdong, China
Start Date
October 1, 2018
Primary Completion Date
April 1, 2020
Completion Date
September 1, 2020
Last Updated
October 17, 2018
NCT06066138
NCT07486219
NCT07485114
NCT06498635
NCT05692635
NCT06305754
Lead Sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions